BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38728857)

  • 1. Letter to the editor: Limitations of acetylcholinesterase inhibitor (AChEI) therapy for Alzheimer's disease.
    Yang G; Wu J; Lei H; Hui Y
    Int J Surg; 2024 May; ():. PubMed ID: 38728857
    [No Abstract]   [Full Text] [Related]  

  • 2. Acetylcholinesterase inhibitors in Alzheimer's disease influence Zinc and Copper homeostasis.
    Giacconi R; Giuli C; Casoli T; Balietti M; Costarelli L; Provinciali M; Basso A; Piacenza F; Postacchini D; Galeazzi R; Fattoretti P; Nisi L; Fabbietti P; Papa R; Malavolta M
    J Trace Elem Med Biol; 2019 Sep; 55():58-63. PubMed ID: 31345366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acetylcholinesterase inhibitors and cognitive stimulation, combined and alone, in treating individuals with mild Alzheimer's disease.
    Devita M; Masina F; Mapelli D; Anselmi P; Sergi G; Coin A
    Aging Clin Exp Res; 2021 Nov; 33(11):3039-3045. PubMed ID: 33763839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Souvenaid® Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer's Disease.
    García-Alberca JM; Gris E; de la Guía P; Mendoza S; de la Rica ML
    J Alzheimers Dis; 2023; 91(4):1459-1469. PubMed ID: 36641676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer's Disease. Review of Reviews.
    Moreta MP; Burgos-Alonso N; Torrecilla M; Marco-Contelles J; Bruzos-Cidón C
    Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prescribing cholinesterase inhibitors in mild cognitive impairment-Observations from the Alzheimer's Disease Neuroimaging Initiative.
    Stage E; Svaldi D; Sokolow S; Risacher SL; Marosi K; Rotter JI; Saykin AJ; Apostolova LG;
    Alzheimers Dement (N Y); 2021; 7(1):e12168. PubMed ID: 35005201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylcholinesterase Inhibitors for Alzheimer's Disease Treatment Ameliorate Acetaminophen-Induced Liver Injury in Mice via Central Cholinergic System Regulation.
    Zhang J; Zhang L; Sun X; Yang Y; Kong L; Lu C; Lv G; Wang T; Wang H; Fu F
    J Pharmacol Exp Ther; 2016 Nov; 359(2):374-382. PubMed ID: 27535978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Retrospective Study on the Benefits of Combined Citicoline, Memantine, and Acetylcholinesterase Inhibitor Treatments in Older Patients Affected with Alzheimer's Disease.
    Castagna A; Fabbo A; Manzo C; Lacava R; Ruberto C; Ruotolo G
    J Alzheimers Dis; 2021; 79(4):1509-1515. PubMed ID: 33459645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
    Taipale H; Tanskanen A; Koponen M; Tolppanen AM; Tiihonen J; Hartikainen S
    Int Clin Psychopharmacol; 2014 Jul; 29(4):216-23. PubMed ID: 24608822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
    Nobili F; Koulibaly M; Vitali P; Migneco O; Mariani G; Ebmeier K; Pupi A; Robert PH; Rodriguez G; Darcourt J
    J Nucl Med; 2002 Aug; 43(8):983-90. PubMed ID: 12163621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Effect of Acetylcholinesterase Inhibitors on the Dorsal Attention Network of Alzheimer's Disease Patients: A Pilot Study Using Resting-State Functional Magnetic Resonance Imaging.
    Yamashita KI; Uehara T; Taniwaki Y; Tobimatsu S; Kira JI
    Front Aging Neurosci; 2022; 14():810206. PubMed ID: 35450059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. White matter hyperintensities in cholinergic pathways may predict poorer responsiveness to acetylcholinesterase inhibitor treatment for Alzheimer's disease.
    Lee LH; Wu SC; Ho CF; Liang WL; Liu YC; Chou CJ
    PLoS One; 2023; 18(3):e0283790. PubMed ID: 37000849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer's Disease.
    Russo P; Kisialiou A; Moroni R; Prinzi G; Fini M
    Curr Drug Targets; 2017; 18(10):1179-1190. PubMed ID: 26424395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA damage, DNA susceptibility to oxidation and glutathione redox status in patients with Alzheimer's disease treated with and without memantine.
    Akkaya Ç; Yavuzer SS; Yavuzer H; Erkol G; Bozluolcay M; Dinçer Y
    J Neurol Sci; 2017 Jul; 378():158-162. PubMed ID: 28566155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Value therapy for Alzheimer's disease--a European perspective.
    Vellas B; Froelich L; Sampaio C
    Alzheimers Dement; 2007 Jul; 3(3):152-6. PubMed ID: 19595930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of therapy with acetylcholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease as reported in the literature.
    El Melik R; Dubil A; Pound MW
    Consult Pharm; 2014 Jun; 29(6):400-7. PubMed ID: 25202893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
    Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
    Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer's disease.
    Relkin NR
    Expert Rev Neurother; 2007 Jun; 7(6):735-48. PubMed ID: 17561789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefits of Treatment with Ginkgo Biloba Extract EGb 761 Alone or Combined with Acetylcholinesterase Inhibitors in Vascular Dementia.
    García-Alberca JM; Mendoza S; Gris E
    Clin Drug Investig; 2022 May; 42(5):391-402. PubMed ID: 35349093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.